Table 1 Clinical characteristics of the clinical population relative to PCSK9 groups
|  | Clinical population n = 539 | Quartile I < 138 ng/L n = 135 | Quartile II–III 138–264 ng/L n = 270 | Quartile IV > 264 ng/L n = 134 | P value |
|---|---|---|---|---|---|
Demographics | |||||
 Age, years | 60 ± 9 | 61 ± 9 | 60 ± 9 | 61 ± 8 | ns |
 Male gender | 326 (60) | 88 (65) | 166 (61) | 72 (53) | 0.1411 |
Clinical characteristics | |||||
 Typical angina | 140 (26) | 30 (22) | 66 (24) | 44 (33) | ns |
 Atypical angina | 321 (60) | 78 (58) | 166 (61) | 77 (57) | |
 Non-anginal chest pain | 78 (14) | 27 (20) | 38 (14) | 13 (10) | |
 LVEF% | 60 ± 8 | 60 ± 9 | 60 ± 9 | 61 ± 7 | ns |
 Pre-test probability of CAD | 48 ± 19 | 48 ± 18 | 48 ± 19 | 49 ± 20 | ns |
Cardiovascular risk factors | |||||
 Family history of CAD | 189 (35) | 40 (30) | 90 (33) | 59 (44) | 0.0328 |
 Diabetes | 160 (30) | 37 (27) | 90 (33) | 33 (25) | ns |
 Hypercholesterolemia | 322 (60) | 77 (57) | 163 (60) | 82 (61) | ns |
 Hypertension | 360 (67) | 88 (65) | 181 (67) | 91 (68) | ns |
 Smoking | 133 (25) | 30 (22) | 69 (26) | 34 (25) | ns |
 BMI, kg/m2 | 27.7 ± 4.3 | 27.9 ± 4.0 | 28.0 ± 4.3 | 26.8 ± 4.6 | 0.0282 |
 Metabolic syndrome | 185 (34) | 54 (40) | 100 (37) | 31 (23) | 0.0059 |
Pharmacological therapies | |||||
 Beta-blockers | 215 (40) | 64 (47) | 105 (39) | 46 (34) | ns |
 Calcium channel blockers | 74 (14) | 21 (16) | 32 (12) | 21 (16) | ns |
 ACE inhibitors | 166 (31) | 43 (32) | 87 (32) | 36 (27) | ns |
 ARBs | 91 (17) | 23 (17) | 43 (16) | 25 (19) | ns |
 Diuretics | 93 (17) | 27 (20) | 44 (16) | 22 (16) | ns |
 Anti-diabetic | 111 (21) | 27 (20) | 66 (24) | 18 (13) | 0.0354 |
 Statins | 279 (52) | 72 (53) | 148 (55) | 59 (44) | ns |
 Aspirin | 316 (59) | 94 (70) | 147 (54) | 75 (56) | 0.0107 |
 Anti-coagulants | 11 (2) | 2 (1) | 5 (2) | 4 (3) | ns |